{"hq_id":"hq-c-mix-000080","name":"Aspergillus fumigatus","context":"human_adult","risk_level":"extreme","schema":"legacy","note":"Synthesis unavailable: compound lacks vectorizable regulatory classifications. Raw safety data returned.","data":{"risk_level":"extreme","summary":"Aspergillus fumigatus is a ubiquitous saprophytic mold and the leading cause of invasive aspergillosis (IA), one of the most lethal fungal infections. Conidia (spores) are 2-3 um in diameter — small enough to penetrate deep into the pulmonary alveoli. Every person inhales hundreds of conidia daily, but intact innate immunity (alveolar macrophages, neutrophils) clears them efficiently. In immunocompromised patients (neutropenia, organ transplant, high-dose corticosteroids, advanced HIV/AIDS), inhaled conidia germinate into hyphae that invade pulmonary vasculature, causing hemorrhagic infarction and dissemination to brain, kidneys, liver, and other organs. Mortality: 30-95% depending on host immune status and timing of diagnosis. Produces gliotoxin (immunosuppressive virulence factor) and other secondary metabolites. Thermotolerant (grows at 37-55C), making it the dominant Aspergillus in human infection. Hospital construction-related outbreaks are well-documented — HEPA filtration and positive-pressure rooms required for high-risk patients. Azole-resistant A. fumigatus (TR34/L98H mutation) is emerging globally, driven by agricultural azole fungicide use, with mortality approaching 90% for resistant IA.","source_refs":["aletheia_fungi_batch_2026"]},"meta":{"synthesis_version":"n/a","timestamp":"2026-07-27T03:50:40.159Z"},"_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult"]}